Biocardia, Inc. 8-K Filing
Ticker: BCDA · Form: 8-K · Filed: Nov 10, 2025 · CIK: 925741
| Field | Detail |
|---|---|
| Company | Biocardia, Inc. (BCDA) |
| Form Type | 8-K |
| Filed Date | Nov 10, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 B |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Biocardia, Inc. (ticker: BCDA) to the SEC on Nov 10, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 B (ch registered Common Stock , par value $0.001 BCDA The Nasdaq Capital Market Indicat).
How long is this filing?
Biocardia, Inc.'s 8-K filing is 2 pages with approximately 514 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 514 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-11-10 08:02:15
Key Financial Figures
- $0.001 B — ch registered Common Stock , par value $0.001 BCDA The Nasdaq Capital Market Indicat
Filing Documents
- bcda20251110_8k.htm (8-K) — 26KB
- ex_885642.htm (EX-99.1) — 12KB
- 0001437749-25-033949.txt ( ) — 170KB
- bcda-20251110.xsd (EX-101.SCH) — 3KB
- bcda-20251110_def.xml (EX-101.DEF) — 11KB
- bcda-20251110_lab.xml (EX-101.LAB) — 15KB
- bcda-20251110_pre.xml (EX-101.PRE) — 11KB
- bcda20251110_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On November 10, 2025, BioCardia, Inc. issued a press release announcing the first patient enrolled at Henry Ford Health in its ongoing Phase 3 CardiAMP HF II clinical trial for patients with ischemia heart failure of reduced ejection fraction. A copy of the press release is attached hereto as Exhibit 99.1 to this current report on Form 8-K. The information in this Item 8.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 BioCardia, Inc. press release dated November 10, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: November 10, 2025